ZYDUSLIFE · Concall Summary
ZYDUS LIFESCIENCES LTD
During the earnings call for Q1 FY27, Zydus Lifesciences reported consolidated revenues of ₹80.2 billion, reflecting a 22% year-on-year increase. The EBITDA margin was 24.1%, with EBITDA at ₹19.3 billion and net profit at ₹9.4 billion. Management highlighted strong growth in the branded formulations business in India, achieving a 20% year-on-year increase, and noted significant contributions from the chronic portfolio. The international formulations business also performed well, with revenues of ₹9.7 billion, up 34% year-on-year. The North America segment showed resilience, with revenues of ₹31 billion, driven by new product launches and market share gains. Management discussed ongoing investments in innovation and expansion, including a joint venture in Sri Lanka and advancements in their biologics pipeline. The call concluded with a Q&A session addressing various operational and financial queries from analysts.
Management emphasized strong growth and positive developments across key business segments.
View source filing →Earlier concalls
- 2026-08-11 — Zydus Lifesciences Limited's investor presentation reported a total revenue growth of 22% year-over-year for the quarter…
- 2026-05-24 — Zydus Lifesciences Limited reported strong performance for Q4 FY26 during its earnings call held on May 19, 2026. Manage…
- 2026-02-15 — During the earnings call held on February 10, 2026, Zydus Lifesciences Limited reported a strong financial performance f…
See ZYDUSLIFE's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free